Ozmosi | Indacaterol Drug Profile

Product Description

Indacaterol is used for the long-term maintenance treatment of air flow blockage in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. COPD is a long-term lung disease that causes bronchospasm (wheezing or difficulty with breathing). Indacaterol is a long-acting bronchodilator. Bronchodilators are medicines that are breathed in through the mouth to open up the bronchial tubes (air passages) in the lungs. They relieve cough, wheezing, shortness of breath, and troubled breathing by increasing the flow of air through the bronchial tubes. (Sourced from: https://www.mayoclinic.org/drugs-supplements/indacaterol-inhalation-route/side-effects/drg-20075006?p=1)

Mechanisms of Action: LAB Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral, Inhalant

FDA Designation: *

Approval Status: Approved

Approved Indications: None

Known Adverse Events: None

Company: Novartis
Company Location: Europe
Company CEO: Vasant Narasimhan
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Indacaterol

Countries in Clinic: Austria, China, Czech Republic, Greece, Hungary, Italy, Portugal, Romania, Spain

Active Clinical Trial Count: 3

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Asthma

Phase 2: Chronic Obstructive Pulmonary Disease

Phase 1: Bronchitis, Chronic|Emphysema

Trial ID	Trial	Phase	Trial Status	Disease	Primary Completion Date	Latest Trial Update Date	Data Updated
CTR20241209	CTR20241209	P1	Completed	Bronchitis, Chronic\|Emphysema\|Chronic Obstructive Pulmonary Disease	2024-07-16	2025-04-29	Patient Enrollment\|Primary Completion Date\|Start Date\|Study Completion Date\|Treatments\|Trial Status
CTR20243686	CTR20243686	P2	Completed	Chronic Obstructive Pulmonary Disease	2025-06-26	2025-07-27	Patient Enrollment\|Primary Completion Date\|Study Completion Date\|Treatments\|Trial Status
2022-501899-26-00	CQMF149G2301	P3	Recruiting	Asthma	2026-08-31	2025-05-02	Treatments

Recent News Events

Date	Type	Title
10/07/2025	News Article	AeroRx Therapeutics Announces $21 Million Series A Financing to Advance Inhaled AERO-007, the First Nebulized LABA/LAMA for COPD, into Late-Stage Clinical Development
09/21/2023	News Article	Bronchial Spasms Treatment Market Size, Growth 2023-2031
09/02/2023	News Article	Despite the challenges posed by Covid-19, the global Anti Asthma Drugs market Size is projected to grow at a CAGR of 5.6% during the 2023 to 2030 period
03/06/2023	News Article	Respiratory Inhalers Market Share ($43.44 Billion by 2028) Driven by Rising Prevalence of Asthma – Global Report by The Insight Partners

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Session Expiring Soon

Indacaterol

Alternative Names: indacaterol, onbrez, qab149, hirobriz, arcapta neohaler, utibron Clinical Status: Inactive Latest Update: 2025-12-22 Latest Update Note: Clinical Trial Update